Avantor (AVTR) vs Bio-Rad Laboratories (BIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Avantor (AVTR) has outperformed Bio-Rad Laboratories (BIO) over the past year, gaining 28.8% versus a gain of 13.3%. Over five years, BIO leads with a -52.2% price change compared with -62.5% for AVTR. Avantor is the larger company by market cap ($10.06 billion vs $9.65 billion), about 1.0 times the size, while Bio-Rad Laboratories is growing revenue faster (+0.7% vs -3.4%).
On valuation, Avantor trades at a lower forward P/E (16.7x vs 36.2x for Bio-Rad Laboratories). Bio-Rad Laboratories converts more of its revenue into profit, with a net margin of 29.4% versus -8.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVTR | BIO |
|---|---|---|
| Share price | $14.84 | $358.90 |
| Market cap | $10.06B | $9.65B |
| 1-day change | -1.85% | -2.34% |
| YTD return | +29.49% | +18.45% |
| 1-year return | +28.82% | +13.32% |
| 5-year return | -62.54% | -52.16% |
| P/E ratio (TTM) | 29.68 | 9.54 |
| Forward P/E | 16.73 | 36.23 |
| EPS (TTM) | $0.50 | $37.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.55B | $2.58B |
| Revenue growth (YoY) | -3.41% | +0.65% |
| Net income (latest FY) | $-530.20M | $759.90M |
| Gross margin | 32.65% | 51.87% |
| Operating margin | -3.76% | 1.83% |
| Net margin | -8.09% | 29.42% |
| 52-week high | $17.45 | $396.23 |
| 52-week low | $7.27 | $236.73 |
| Distance from 52-week high | -14.96% | -9.42% |
| Analyst consensus | hold | hold |
| Avg. price target upside | +16.91% | -0.62% |
| Average volume | 8.77M | 257.70K |
| Shares outstanding | 677.62M | 21.83M |
| Employees | 13,500 | 7,450 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVTR has outperformed BIO by 15.5 percentage points over the past year.
- Avantor trades at a higher earnings multiple (29.7x vs 9.5x trailing P/E).
- Bio-Rad Laboratories is more profitable, keeping 29.4 cents of every revenue dollar as net income versus -8.1 cents for Avantor.
About Avantor
AVTR stock →Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.
Industrials · Biotechnology: Laboratory Analytical Instruments · 13,500 employees
About Bio-Rad Laboratories
BIO stock →Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
Industrials · Biotechnology: Laboratory Analytical Instruments · 7,450 employees
AVTR vs BIO FAQ
Which is bigger, Avantor or Bio-Rad Laboratories?
Avantor (AVTR) is larger, with a market capitalization of $10.06B compared with $9.65B for Bio-Rad Laboratories (BIO).
Which stock has performed better over the past year, AVTR or BIO?
AVTR returned +28.82% over the past 12 months, compared with +13.32% for BIO (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AVTR or BIO?
BIO has the lower trailing P/E at 9.5, versus 29.7 for AVTR. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Avantor and Bio-Rad Laboratories in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.